Skip to main content
Research

Institutional Requirements and Recognitions

The structure has recognitions and accreditations released by national and regional bodies, which certify their suitability to operate in the field clinical, healthcare and Research, according to high standards of quality e competence.

  • Registration in the National Research Registry, art. 64, paragraph 1, Presidential Decree 11 July 1980 n° 382 and subsequent amendments with communication of 25.09.2023 prot. 18181 of the Ministry of University and Research, Definitive Code 001756_IMPR;
  • Recognition to “Outpatient Center for Clinical Trials of Phase II and III Drugs, for patients only, excluding healthy volunteers, pregnant women and subjects under the age of 18 years” with Resolution No. 1220 of 09.09.2014 of ASL Milano and next inclusion in the AIFA list of Centers Authorized to conduct "Clinical pharmacological trials""; he confirms ATS Milan with provision prot. n. 183380/21 of 8.11.2021;
  • Recognition on date 01.04.2015 with DGR X/3350 as Presidium of the Regional Network for Rare Diseases, for pathologies Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, and Chronic Inflammatory Demyelinating Polyneuropathy;
  • Recognition on date 26.10.2020 with DGR 3711 as a Presidium of the regional network for Rare Diseases, for the pathologies: Myotonic dystrophy type 1 (Steinert's disease); Myotonic dystrophy type 2 (proximal myotonic myopathy); Myotonia congenita type 1 (Thomsen's disease); Myotonia congenita type 2 (Becker's disease); Congenital paramyotonia of von Eulenburg and familial periodic paralysis;
  • Recognition on date 24.07.2023 with DGR XII/725 as a regional network for rare diseases, for 7 pathologies of the central and peripheral nervous system: Amyotrophic Lateral Sclerosis; Primary Lateral Sclerosis; Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor Neuropathy; Lewis Sumner Syndrome; Myotonic Dystrophies; Normokalemic, Hypokalemic, and Hyperkalemic Paralyses;
  • Center authorized as a center for the diagnosis and treatment of Multiple sclerosis with the drugs provided for by the AIFA note 65 (Regional note G1.2019.0023116 of 06/18/2019 and subsequent amendments); of 02/11/2022;
  • Company validation by the European Commission's Research Executive Agency (REA) and confirmation of the PIC (Personal Identification Code);
  • With regard to the approval of research projects, the Structure reports to the Territorial Ethics Committee Lombardy 3, Reference structure: IRCCS Ca' Granda Foundation, Maggiore Polyclinic Hospital;
  • Joining date 05/01/2015 at the Life Sciences Cluster, a tool for valorising and relaunching the sector in terms of competitiveness Life Sciences (LS) in Lombardy;
  • Recognition from Lombardy Region dated 24.02.2017, as Center for Cognitive Disorders and Dementia (CDCD) and inclusion in the online map of dementia services available on the Dementia Observatory website (www.iss.it/demenze), entirely dedicated to dementia within the ISS portal and with a direct link to the Ministry of Health website;
  • Recognition to Prescribing Center for drugs referred to in AIFA NOTE 79, March 2016, With the 'Authorization to prescribe therapeutic plans on a specific AIFA platform;
  • Recognition to Authorized Center for the Preparation of the Therapeutic Plan for Anticholinesterase Drugs, from 30.11.2015, of which the AIFA Note 85